文献速递膀胱癌与上尿路尿路上皮癌

再次电切分期对高级别T1非肌层浸润性膀胱癌风险分层的预后影响

Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
PubMed 文献 · BJU Int · 2026-03-03

这项多中心回顾性研究纳入1403例接受充分BCG治疗的原发或继发T1高级别NMIBC患者,评估再次电切病理分期对EAU2021风险分层的预后价值。结果显示38.8%有残留病变,17.7%持续T1;持续T1与更差的无高级别复发生存、无进展生存和癌症特异性死亡独立相关,且在高危和极高危组5年进展率高达48%。

要点

  • 再次电切发现持续T1者预后显著差于T0/Ta,5年癌症特异性死亡率从6-7%升至23%。
  • 持续T1是多变量分析中无高级别复发生存(HR 2.40)、无进展生存(HR 3.10)和癌症特异性死亡(HR 3.00)的独立不良因素。
  • 高危和极高危组中持续T1患者5年进展率高达48%,标准BCG可能不足。

核心结论

  • 再次电切残留T1与BCG治疗的T1高级别NMIBC不良长期肿瘤学结局强相关,并显著降低统计治愈可能性。
  • 高危和极高危患者中持续T1代表生物学不良亚组,标准BCG可能不充分。

研究设计与样本

  • 回顾性多中心研究,纳入2007至2020年间28个欧洲学术中心接受TURB、再次TURB和充分BCG治疗的原发或继发T1高级别NMIBC患者1403例。
  • 按再次TURB病理分期(T0、Ta、Tis、T1)和EAU2021风险组分层,采用Kaplan-Meier、Cox回归和竞争风险方法分析。

主要发现

  • 再次TURB时38.8%患者有残留病变,其中17.7%为持续T1。
  • 与T0/Ta相比,持续T1者5年无高级别复发生存和无进展生存显著更低,高级别复发超过一半,高危和极高危组5年进展率高达48%。
  • 5年癌症特异性死亡率从T0/Ta的6-7%升至T1的23%。
  • 多变量分析显示残留T1独立与更差的无高级别复发生存(HR 2.40)、无进展生存(HR 3.10)和癌症特异性死亡(HR 3.00)相关。
  • 治愈模型显示残留T1的治愈比例低于T0/Ta。

临床怎么用

  • 对T1高级别NMIBC患者,再次电切病理分期有助于识别BCG治疗效果不佳的高危亚组。
  • 持续T1患者可能需要更积极的治疗策略或临床试验,而非仅标准BCG。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 未报告其他具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the prognostic impact of T-stage at re-transurethral resection of bladder (TURB) and its utility for refining risk stratification across European Association of Urology 2021 (EAU21) risk groups in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette-Guérin (BCG). PATIENTS AND METHODS: Retrospective multicentre study including patients with primary or secondary T1HG NMIBC treated with TURB, re-TURB, and adequate BCG between 2007 and 2020 across 28 European academic centres. Patients were stratified according to re-TURB pathological stage (T0, Ta, Tis, T1) and EAU21 risk groups. Kaplan-Meier, Cox regression, and competing-risk methods were used to evaluate recurrence-free survival (RFS), HG-RFS, progression-free survival (PFS), and cancer-specific mortality (CSM). A mixture cure model estimated statistical cure fractions for the overall cohort. RESULTS: Among 1403 patients, residual disease at re-TURB was identified in 38.8%, including 17.7% with persistent T1. Residual T1 was consistently associated with worse outcomes. Compared with T0/Ta, persistent T1 at re-TURB showed substantially lower 5-year HG-RFS and PFS, with high-grade recurrence in over half of patients and 5-year progression up to 48% in high- and very high-risk groups. The 5-year CSM rose from 6-7% (T0/Ta) to 23% (T1). On multivariable analysis, residual T1 was independently associated with worse HG-RFS (hazard ratio 2.40), PFS (hazard ratio 3.10), and CSM (hazard ratio 3.00). Cure modelling showed lower cure fractions for residual T1 compared with T0/Ta. CONCLUSION: Residual T1 at re-TURB is strongly associated with adverse long-term oncological outcomes in BCG-treated T1HG NMIBC and markedly reduces the likelihood of statistical cure. High- and very high-risk patients with persistent T1 represent a biologically adverse subgroup in whom standard BCG may be insufficient.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Fernández-Mardomingo A, Subiela JD, Artiles Medina A, et al. Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups. BJU Int. 2026. PMID: 41773726. doi:10.1111/bju.70207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。